The Greek pharmaceutical company ELPEN is funding GRECCO-19, a clinical study which researches the active substance colchicine as a possible response treatment for the COVID-19 pandemic, the company said in a statement.

The first results from 60 Greek patients with coronavirus that took colchicine were very encouraging in terms of complications of the virus to the heart and the lungs, said Professor of Cardiology Christos Stefanadis to Athens-Macedonian News Agency on Monday.